



ASX and Media Release

## **Viralytics' \$4.1m Entitlement Offer Closes Fully Subscribed**

- New Shares to be issued under Entitlement Offer on 5 March 2014
- First Tranche of Placement successfully raised \$6.1m
- Second Tranche of Placement to raise \$16.9m subject to shareholder approval at General Meeting on 6 March

---

**28 February 2014, Sydney, Australia:** The Viralytics Limited (ASX:VLA, OTC:VRACY) Entitlement Offer closed on 25 February fully subscribed raising \$4.1 million.

The Entitlement Offer comprising a 1 for 6 non-renounceable rights issue and a top up facility for ordinary Viralytics shares at \$0.28 per share was capped at \$4.1 million. Viralytics received applications for additional shares under the top up facility which, when combined with applications for shareholder rights issue entitlements, resulted in the company needing to scale back some top up applications. Refunds as required will be issued following allotment of the New Shares.

The Entitlement Offer follows the successful completion of the first tranche placement on 5 February 2014 raising \$6.1 million and is to be followed by completion of the second tranche placement to raise \$16.9 million, subject to shareholder approval at a General Meeting on 6 March 2014.

If the second placement is approved Viralytics will complete its transformational \$27.1 million capital raising. The proceeds from the equity raising are to fund the company to the end of 2016 and the three key clinical trials: CALM, STORM and a randomised melanoma trial in this period.

Viralytics' Chief Executive Officer Dr Malcolm McColl said: "We are delighted that the Entitlement Offer has seen such strong demand from shareholders and thank them for their support. The additional funds raised under the Entitlement Offer will provide further support to the company in progressing our key clinical trials and will place us in a strong position to optimise commercial outcomes."

Settlement of the Entitlement Offer is scheduled for 4 March 2014 with the issue and allotment of the New Shares on the following day, and ASX trading of the New Shares expected to commence on 6 March 2014.

Shareholders wanting to trade any New Shares allocated to them under the top up facility should confirm their allocation before doing so (prior to receiving their holding statement).



Shareholders can contact Viralytics' share registry from 8.30am to 5.30pm (AEDT) on 1800 550 560 (within Australia) or +61 1800 550 560 (outside Australia) Monday to Friday.

**Enquiries:**

**Dr Malcolm McColl**  
**Chief Executive Officer**  
**02 9988 4000**

**Mr Rudi Michelson**  
**Monsoon Communications**  
**03 9620 3333**

---

**About Viralytics Ltd:**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells provides the potential for low toxicity in the patient.

The company has fully enrolled a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites soon.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.